A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of treatment with the combination Avastin
(bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14
of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally
advanced or metastatic colorectal cancer. The anticipated time on study treatment is until
disease progression.